Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
Casado, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Rosas, José (Hospital Marina Baixa (La Vila Joiosa, Alacant))
Rubio-Terrés, Carlos (Health Value)
Rubio-Rodríguez, Darío (Health Value)
Boolell, Mitra (Medical Affairs)
Arístegui, Ignacio (Medical Affairs)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	To estimate the cost-effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35 mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70 mg tablets (ALN) in Spain. A probabilistic analysis (second-order Monte Carlo simulation) was performed with a time horizon of 5 years, from the perspective of the Spanish National Health System. The bone fracture probabilities were obtained from a cohort study of 3614 women from USA with PMO treated with RIS-GR (1807) or ALN (1807) (Thomasius, 2022). The pharmacological cost and the cost of fractures were obtained from Spanish sources (€ 2022). The utilities of patients with and without fracture (quality-adjusted life years [QALYs]) were obtained from the medical literature. Compared with ALN, treatment with RIS-GR can avoid 79 fractures (between 75 and 82) every 1000 patients treated, and 0. 0119 QALYs would be gained (between 0. 0098 and 0. 0140) per patient. Additionally, GR-RIS would generate a cost saving per patient of €1994 (€1437-2904) with a probability of 99. 7%. The scenario analyses confirmed the stability of the base case results. According to this study, RIS-GR would be the dominant treatment (lower costs with QALY gain) compared with ALN. In a context of scarcity of resources, it is important to analyze the economic impact of the differences in persistence and probability of fractures of postmenopausal osteoporosis treatments. An economic model of the probabilistic type was carried out, with the aim of estimating the cost-effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35 mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70 mg tablets (ALN) in Spain. In a period of 5 years, due to the lower probability of bone fractures observed with RIS-GR versus ALN, for every 1000 patients, 79 fractures would be avoided. In addition, 0. 0119 QALYs would be gained and €1994 saved per patient treated with RIS-GR. Weekly RIS-GR 35 mg is a dominant treatment (lower costs with QALY gain) for PMO compared with weekly ALN 70 mg in Spain.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Alendronate ; Cost-effectiveness ; Postmenipausal osteoporosis ; Risedronate gastro-resistant
Published in:	Journal of Comparative Effectiveness Research, Vol. 12 (september 2023) , ISSN 2042-6313

DOI: 10.57264/cer-2023-0115
PMID: 37712635

11 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles